Fedotozine

Fedotozine
Clinical data
Routes of; administration	Oral
ATC code	None;
Legal status
Legal status	In general: non-regulated;
Identifiers
	IUPAC name (2R)-N,N-dimethyl-2-phenyl-1-[(3,4,5-trimethoxybenzyl)oxy]-2-butanamine;
CAS Number	123618-00-8 ; 133267-27-3 (tartrate);
PubChem CID	6918160;
ChemSpider	5293373;
UNII	F45VW2087W;
ChEMBL	ChEMBL2106275;
CompTox Dashboard (EPA)	DTXSID901318556 ;
Chemical and physical data
Formula	C22H31NO4
Molar mass	373.493 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O(c1cc(cc(OC)c1OC)COC[C@@](c2ccccc2)(N(C)C)CC)C;
	InChI InChI=1S/C22H31NO4/c1-7-22(23(2)3,18-11-9-8-10-12-18)16-27-15-17-13-19(24-4)21(26-6)20(14-17)25-5/h8-14H,7,15-16H2,1-6H3/t22-/m0/s1; Key:MVKIWCDXKCUDEH-QFIPXVFZSA-N;

Fedotozine (INN; JO 1196 for the (-) tartrate salt) is an opioid drug which acts as a peripherally specific selective κ₁-opioid receptor agonist with preference for the κ_1A subtype.^[1] It was under investigation for the treatment of gastrointestinal conditions like irritable bowel syndrome and functional dyspepsia and made it to phase III clinical trials,^[1]^[2]^[3] but ultimately development was discontinued and it was never marketed.

References

^ ^a ^b Delvaux M (January 2001). "Pharmacology and clinical experience with fedotozine". Expert Opinion on Investigational Drugs. 10 (1): 97–110. doi:10.1517/13543784.10.1.97. PMID 11116283. S2CID 41361900.
^ Barber A, Gottschlich R (October 1997). "Novel developments with selective, non-peptidic kappa-opioid receptor agonists". Expert Opinion on Investigational Drugs. 6 (10): 1351–68. doi:10.1517/13543784.6.10.1351. PMID 15989506.
^ Lembo A (2006). "Peripheral opioids for functional GI disease: a reappraisal". Digestive Diseases. 24 (1–2): 91–8. doi:10.1159/000090312. PMID 16699267. S2CID 29627937.